Item 7.01 Regulation FD Disclosure
On June 16, 2022, Moleculin Biotech, Inc. (the “Company”), issued a press
release and reported preliminary results from the first cohort of the Company’s
first-in-human Phase 1a study of WP1122.
A copy of the press release is attached to this report as Exhibit 99.1 and is
incorporated by reference herein.
The information contained in Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, is being furnished and shall not be “filed” for the
purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor
shall it be incorporated by reference in any filing under the Exchange Act or
the Securities Act of 1933, as amended (“Securities Act”), unless specifically
identified therein as being incorporated by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 99.1 Press Release dated June 16, 2022
104 Cover page Interactive Data File (formatted as Inline XBRL document)
© Edgar Online, source Glimpses